Member Info for inanaco

Now something like this MAB ............ could be upgraded to Avidmab .. the Toxic cargo dropped in exchange for direct killing by the Mab ... rather than carrying a payload to kill ....

all possibilities ....

• Strong results in Phase 2 study for mTNBC
– 29% ORR in 85 patients treated
– Promising durable responses
• Achieved median PFS / OS of 6.0 / 18.8 months, respectively
– Acceptable safety profile in heavily pretreated patients

https://www.immunomedics.com/sacituzumab-govitecan-immu-132/

bi-specific Mab carrying a toxic payload ... ie chemo

so what is Moditope Modi1 worth in TNBC

Rounding out the top five are drugs from Bristol-Myers Squibb, Novartis, FibroGen and Immunomedics—and the group is rife with interesting backstories. Take sacituzumab govitecan, for example: The TNBC therapy, with an estimated $1.44 billion in 2024 sales, was slapped back by the FDA in early 2019 on problems at a manufacturing plant. The fallout from that CRL included a top-level shakeup at the company—but it has since refiled and has high hopes for its FDA decision date in June.

https://www.massgeneral.org/dermatology/treatments-and-services/melanoma-pigmented-lesion-center

Chester 18 ... one should consider the size of these US hospital clinics and the catchment area prestigious private care can pool from (patient numbers) if they also engage in clinical trials ..

https://www.massgeneral.org/cancer-center/treatments-and-services/melanoma?utm_source=google&utm_medium=cpc&utm_campaign=cancerppc&utm_content=Skin_Cancer_Treatments&utm_term=%2Bmelanoma%20%2Bcenter&gclid=EAIaIQobChMIpbLj89m_5wIVBLDtCh0Q1QI8EAAYASAAEgLwCfD_BwE

so what happened with TCR

Ruck ...

ATB another example missing in 2017

missed

Homocitrulline

we do know ....

PD-1 actually has invigorated patients immune system

SCIB1 results show it invigorated the immune system

now just because you have lost MHC expression ...........

that does NOT stop Avidmab ...

Pd-1 tries to recover exhausted T cells ... and to block the cancers ability to use PD-1 as a weapon

SCIB1 replaces exhausted T cells with High Avidity ...

but can still fail in patients that do not express the antigens ie MHC1 loss ...

a lot of work has gone on to try and restore MHC loss .. both Cd4 and Cd8

so that could affect both Immunobody and Moditope ...

but the design of both vaccines are to try and restore via "pro Inflammatory signals"

so Immunobody and Moditope will still have patients you just cannot help .. that restoration maybe a step to far

that is why the trials will give us "efficacy levels" and one reason why i will never post that the Mouse data of 100% could transfer to Humans at 100% ...

"""wouldn't this be counterbalanced by the fact that the higher MDSC level results in a POORER outcome? """

MDSC are suppressing the naturally developed immune response

your Giving Moditope ... which directly targets the effects of MDSC ...

so all you need is the cancer cells to express or forced to express Homocitrullination epitopes (maybe with the help of amplivant) and that response becomes dominate over the cancers ability to hide

its about Tipping the balance to the immune system ...

this is actual trial Data ............ not Mouse

Ample evidence supports a close association between MDSC accumulation and clinical outcome in cancer patients (50, 51). Recent meta-analysis of the studies of 442 patients with various solid tumors demonstrated that MDSC were highly significantly associated with poor overall and progression-free survival (52). MDSC have been implicated in resistance to anti-cancer therapies including sunitinib (53), cisplatin and other chemotherapeutics in lung cancer (54–56), and doxorubicin and melphalan in multiple myeloma (57). Recent studies show an association of MDSC level with patient response to CTLA4/ipilimumab (58, 59) and PD-1 (60, 61).

The fact that MDSC play an important role in the regulation of tumor growth has stimulated the search for a way to therapeutically target these cells.

so if you have high levels MDSC .................. you will have Homocitrullination because its a chemical reaction

its the function of the hijacked MDSC is to suppress the immune system ..

The act of suppression exposes the cancer to Modi2 ....

That is why its Brilliant .

Ruck

Homocitrullination occurs as a result of MPO released by myeloid-derived
suppressor cells (MDSC) which converts thiocyanate to cyanate in the presence
of H2O2

""""However, in cancer, myeloid cells are largely converted to serve a new master – tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils and monocytes. MDSC are not present at steady state in healthy individuals and appear in cancer and pathological conditions associated with chronic inflammation or stress. ""

and ..... Avidmabs can activate MDSC .. because it releases "Damp"

""Classical activation of these cells takes place in a response to strong signals that usually come in form of pathogen-associated molecular patterns (PAMPs) or danger-associated molecular patterns (DAMPs) molecules.""

so part of the way cancer hijacks to suppress the immune system is what triggers "Modi2"

its Brilliant but you will probably complain about me "rambling" but if you study it ... and look at the pictures in the presentation you will see DAMP release in Avidmab

Wild worth a read ... very easy to tie this paper to Homocitrulline and why it could be so effective

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5426480/

we have to accept some seriously smart people are playing with our technology . and the reason why they have to evaluate

we have Killer Mabs ......... that can instigate an immune response via Damage-associated molecular patterns and its the only state on this BB that "Damps" are actually useful ....

and TCR of Killer CD4

leading edge stuff ... ie nothing to compare with easily ...

could be even higher now Avidmab is in the picture and TCR, i am sure we will know more in 2020

and of course a TCR deal gives you some indicator of value and importance that should be bestowed on Modi1/2/3

after all if BioNtech are convinced why would you not be ... ? and the market

tick tock

you can only be damp for so long .... watch out for trench foot

it was not an estimate ...

just to be clear ...

i cant predict the SP over this timescale ...

ask Ivy and Knowlesi they have the credentials to crystal ball gazing in caravans ...